|
| 1 |
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation
Jieun Uhm
Blood Res.2023;58(S1):S109-S113. Published online 2023 April 30
DOI: http://dx.doi.org/10.5045/br.2023.2023054
|
|
| 2 |
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
Jae Joon Han
Blood Res.2023;58(S1):S58-S65. Published online 2023 April 7
DOI: http://dx.doi.org/10.5045/br.2023.2023035
|
|
| 3 |
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng
Cancer Res Treat.2023;55(3):841-850. Published online 2023 February 13
DOI: http://dx.doi.org/10.4143/crt.2022.1438
|
|
| 4 |
Clinical Impact of Drug Adherence of Tyrosine Kinase Inhibitors in Children with Ph-Positive Acute Lymphoblastic Leukemia
Jun-Xia Wang, Miao-Miao Yang, Li-Peng Liu, Hui-Min Zhang, Meng-Chuan Wang, Yu-Wen Chen, Xiao-Ying Zang, Fang Hu
Cancer Res Treat.2023;55(3):1023-1030. Published online 2023 February 6
DOI: http://dx.doi.org/10.4143/crt.2022.1618
|
|
| 5 |
GBA inhibition suppresses ovarian cancer growth, survival and receptor tyrosine kinase AXL-mediated signaling pathways
Gang Wang, Baisha Ouyang, Fang Jing, Xiaoyan Dai
|
|
| 6 |
Effect of Afatinib for Lung Cancer on Papillary Thyroid Carcinoma
Sang Hwon Cho, Jin Seok Lee, Hyeok Jun Yun, Yong Sang Lee, Hang-Seok Chang
|
|
| 7 |
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
Seo-Yeon Ahn, Sang Kyun Son, Gyu Hyung Lee, Inho Kim, June-Won Cheong, Won Sik Lee, Byung Soo Kim, Deog-Yeon Jo, Chul Won Jung, Chu Myoung Seong, Jae Hoon Lee, Young Jin Yuh, Min Kyoung Kim, Hun-Mo Ryoo, Moo-Rim Park, Su-Hee Cho, Hoon-Gu Kim, Dae Young Zang, Jinny Park, Hawk Kim, Seryeon Lee, Sung-Hyun Kim, Myung Hee Chang, Ho Sup Lee, Chul Won Choi, Jihyun Kwon, Sung-Nam Lim, Suk-Joong Oh, Inkyung Joo, Dong-Wook Kim
Blood Res.2022;57(2):144-151. Published online 2022 June 30
DOI: http://dx.doi.org/10.5045/br.2022.2021137
|
|
| 8 |
Lung Related Complications in Patients with Advanced Thyroid Cancer during Lenvatinib Therapy: Case Series and Literature Review
Jee Hee Yoon, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
|
|
| 9 |
FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs
Jae-Sook Ahn, Hyeoung-Joon Kim
Blood Res.2022;57(S1):32-36. Published online 2022 April 30
DOI: http://dx.doi.org/10.5045/br.2022.2022017
|
|
| 10 |
PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI–Resistant Metastatic Clear Cell Renal Cell Carcinoma
Se Un Jeong, Hee Sang Hwang, Ja-Min Park, Sun Young Yoon, Su-Jin Shin, Heounjeong Go, Jae-Lyun Lee, Gowun Jeong, Yong Mee Cho
|
|
| 11 |
Nilotinib-Induced Acute Interstitial Nephritis during the Treatment of Chronic Myeloid Leukemia
Min Jeong Kim
Kosin Med J.2021;36(2):153-160. Published online 2021 December 31
DOI: http://dx.doi.org/10.7180/kmj.2021.36.2.153
|
|
| 12 |
Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer
Young Kee Shong
|
|
| 13 |
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
Cancer Res Treat.2022;54(2):434-444. Published online 2021 August 2
DOI: http://dx.doi.org/10.4143/crt.2021.671
|
|
| 14 |
NOX4/Src regulates ANP secretion through activating ERK1/2 and Akt/GATA4 signaling in beating rat hypoxic atria
Cheng-zhe Wu, Xiang Li, Lan Hong, Zhuo-na Han, Ying Liu, Cheng-xi Wei, Xun Cui
|
|
| 15 |
Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey
Jieun Uhm, Kyoung Ha Kim, Hyewon Lee, Hawk Kim, Slader Cassandra, Inkyung Joo, Chul Won Jung
Blood Res.2021;56(1):31-37. Published online 2021 January 28
DOI: http://dx.doi.org/10.5045/br.2021.2020260
|
|
| 16 |
Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey
Mesut Göçer, Erdal Kurtoğlu
Blood Res.2020;55(4):206-212. Published online 2020 December 31
DOI: http://dx.doi.org/10.5045/br.2020.2020158
|
|
| 17 |
Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy
Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
J Liver Cancer.2020;20(2):160-166. Published online 2020 September 30
DOI: http://dx.doi.org/10.17998/jlc.20.2.160
|
|
| 18 |
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat.2020;52(4):1288-1290. Published online 2020 June 22
DOI: http://dx.doi.org/10.4143/crt.2020.278
|
|
| 19 |
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
Ying Lin, Mingxi Lin, Jian Zhang, Biyun Wang, Zhonghua Tao, Yiqun Du, Sheng Zhang, Jun Cao, Leiping Wang, Xichun Hu
Cancer Res Treat.2020;52(4):1059-1066. Published online 2020 April 24
DOI: http://dx.doi.org/10.4143/crt.2019.633
|
|
| 20 |
RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer
Tian-Hao Weng, Min-Ya Yao, Xiang-Ming Xu, Chen-Yu Hu, Shu-Hao Yao, Yi-Zhi Liu, Zhi-Gang Wu, Tao-Ming Tang, Pei-Fen Fu, Ming-Hai Wang, Hang-Ping Yao
Cancer Res Treat.2020;52(3):973-986. Published online 2020 April 22
DOI: http://dx.doi.org/10.4143/crt.2019.726
|
|
